Subscribe

Web Exclusives

In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones.
In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones.
In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones.
In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones.
In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones.
In this newsletter, we will discuss benefit design considerations for multiple myeloma, with a focus on treatment pathways and information technologies that can be used to improve patient care.
In this fifth issue, we will focus on the economic implications of newer agents used to treat myeloma-related bone disease.
In this fourth issue, we will focus on the value of incorporating best practices for managing treatment-related toxicities.
In this third issue, we will be focusing on the impact of novel agents on myeloma-associated renal impairment.
In this second issue, we will focus on the relevance of end points in clinical trials for myeloma.
Page 5 of 6
Results 41 - 50 of 51
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology